What does it mean if the volume is large but minimal price movement?

Welcome...

"Interpretation
The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, is safe and well tolerated at all tested doses in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients on day 42. Two-dose immunisation with 4 μg vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres than the single 8 μg dose or 4 μg dose on days 0 and 14.

The China National Biotec Group and the Beijing Institute of Biological Products provided the study product, and oversaw all trial operations."

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30831-8/fulltext


"The vaccine candidate was jointly developed by the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products – subsidiaries of the SinoPharm unit, China National Biotec Group (CNBG)."

https://webcache.googleusercontent.com/search?q=cache:aXGede2j6-gJ:https://www.thestar.com.my/news/regional/2020/07/23/coronavirus-chinese-pharmaceutical-firm-says-covid-19-vaccine-may-be-ready-this-year+&cd=3&hl=en&ct=clnk&gl=my

China's largest, and the world's fifth human vaccine research, development, and manufacturing enterprise Sinopharm saw a visit from Ambassadors and senior diplomats from 50 African countries on Thursday to deepen cooperation in the fight against the Covid-19 pandemic and build a better China-Africa health community.

Chinese President Xi Jinping expressed back in May that developed Chinese Covid-19 vaccines will be a "global public good" - accessible and affordable to developing countries, especially those in Africa.

https://www.africanews.com/2020/10/16/50-african-diplomats-on-anti-covid-19-visit-to-china-s-sinopharm/

Proposed Private Placement is still in the preliminary stage and application to the authorities will be made within 2 months from the date of the announcement. Anyway as long as the proceeds from the private placement will be put to good use for the future growth of the company as explained c in the Bursa Malaysia disclosure, the effects of private placement will only be temporary.

"ESTIMATED TIMEFRAME FOR COMPLETION
Barring any unforeseen circumstances and subject to all required approvals being obtained,
the Proposed Private Placement is expected to be completed by the FIRST QUARTER of 2021.

APPLICATION TO THE AUTHORITIES
The application to the relevant authorities shall be made WITHIN 2 MONTHS from the date of this
announcement.

FUTURE PROSPECTS OF THE GROUP
In accordance with its strategy to continuously grow its existing business, the Group
had relocated the main bamboo processing and manufacturing plant out of Ganzhou,
and entered into a public private partnership arrangement on a 70:30 basis with the
local authority of Jingzhou, China to develop a new high-tech bamboo processing plant
and research and development center. The aforesaid plant is currently under testing
phase and is expected to commence commercial operations in November 2020, and is
surrounded by an estimated 18,200 metric tonnes of ready-to-harvest raw bamboo,
which will be used for the manufacturing of bamboo products, processing of bamboo
related foodstuff and bamboo eco-tourism in the near future.

In addition, the Group has put in place a research and development team to develop
new range of eco-friendly products to ensure the Group is able to continue catering to
the demands of customers and remain competitive in the industry. The Group being
the sole exclusive distributor in the China for "Classen", a brand of a high-end wood
flooring products originated from Germany, and will continue to focus its efforts to
promote and sell Classen's products. The proceeds raised from the Proposed Private
Placement will ensure that the Group has sufficient working capital for its existing
business to weather any potential headwinds in the short to medium term.

Further, in view of the positive outlook of the healthcare industry as set out in Section
3.6 of this announcement, the management is of the view that now is a timely
opportunity for the Group to venture into a new business, which has growing demand
and may yield favorable and sustainable earnings to the Group over the medium to
long term.
(Source: Management of Kanger)

RATIONALE AND JUSTIFICATIONS FOR THE PROPOSED PRIVATE PLACEMENT
After due consideration of the various methods of fund-raising, the Board is of the view that the
Proposed Private Placement is the most appropriate avenue of fund-raising as the Proposed
Private Placement:-
i. Enables the Company to raise additional funds without incurring interest costs as
compared to conventional bank borrowings;
ii. Provides the Company with an expeditious way of raising funds from the capital market
as opposed to other forms of fund-raising; and
ii. Increases the size and strength of the Company's shareholders' funds.
For shareholders' information, the Company had not undertaken any other equity fund raising
exercises in the past 12 months prior to the date of this announcement.

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=107904&name=EA_GA_ATTACHMENTS

Sure anot? I dont want to be trapped

https://www.tradingview.com/chart/KANGER/3v0NqsvU-KANGER/

Always enter before operator or shark start to pump and not after. Thats my advise to you. You make the final decision yourself.

Im confident with this counter so i am holding. Just look at HWGB suddenly shoot up. By the time it shoots up it will be too late to chase.

Congrats to all who profit. I missed the boat last time.

@rezzare nobody paid me to share. Maybe you should pay me instead kekeke

Will China Supply Much of the World’s Vaccine for COVID-19? WHO In Discussions to do Just That.

The World Health Organization (WHO) now purportedly considers China as its strategic COVID-19 vaccine supplier as the world’s most populous nation—representing the second largest GDP rapidly gaining on the United States—makes its moves to become the world’s primary vaccine supplier.

https://www.trialsitenews.com/will-china-supply-much-of-the-worlds-vaccine-for-covid-19-who-in-discussions-to-do-just-that/

@share2014. Explain yourself. Why do you say so?

Regarding sand
https://www.theedgemarkets.com/article/government-issues-11-aps-river-sand-exports

KLCI expected to consolidate to 1,520-1,550 next week

https://www.theedgemarkets.com/article/klci-expected-consolidate-15201550-next-week

Just my gut feeling that tomorrow the stock movement will be uptrend. However, enter at your own risk. I may be right or i may be wrong.

Summary of results and status updates
https://www.insage.com.my/BursaNews/Attachment/202008/20200819/KANGER-AN20200819A4-2.pdf

@Sepolcmd Thats a pretty good question. Have to ask the sharks haha Maybe they haven't noticed this counter yet.

KINGMAKER

The former ruling party United Malays National Organisation (UMNO) is seen as a key player and who they back could very well make, or break, Anwar's chances at securing the premiership.

UMNO is the largest bloc in Muhyiddin's seven-month-old administration, which has so far survived on a two-seat parliamentary majority.

But UMNO party leaders have become increasingly unhappy with having to follow instructions from a minority party prime minister.

UMNO announced late Tuesday that it would stop supporting Muhyiddin's government unless he agrees to some new conditions, and some party leaders later said it would not be surprising if they decide to back Anwar.

"UMNO is just not used to playing second fiddle, which is the main cause of the leadership challenge. By backing Anwar, the party could demonstrate its ability to decide who becomes the prime minister," said Adib Zalkapli, a director with political risk consultancy BowerGroupAsia.

https://www.theedgemarkets.com/article/fight-malaysias-premiership

In my opinion, the impact will not be significant or rather minimal. This is because UMNO is currently the kingmaker and has the power to decide who becomes PM if you have been following the news lately. In other words, either way, UMNO wins.

CanSino covid vaccine Is based on adenovirus vector vaccine platform similar to johnson and Johnson and AstraZeneca which have reported major side effects recently. Hence i am bit skeptical. I think now they are also considering the possibility of mRNA vaccine (another unproven technology). However , Sinopharm and Sinovac covid vaccines are traditional Inactivated vaccine platform whose safety and efficacy profile is well established and proven.

One thing you need to understand regarding phase 3 clinical trials is that it is conducted under controlled and well regulated conditions. In addition, the sample size (number of patients) enrolled in clinical trials is limited. Hence, only the more common side effects may be detected during the clinical trials. It is only after approval and rolling out of the vaccine, will we be able to study the effects of the vaccine in the real world on large number of people (Phase 4 post marketing surveillance). It is during this time, where rare and very rare side effects which may potentially be serious may be detected. Hence, why would you want to become the guinea pig of a vaccine using new unproven technologies (there are no approved mRNA vaccines and very limited approval of adenovirus vector vaccine prior to this by stringent regulatory authorities. Stringent regulatory authorities refer to US FDA and European Medicine Agency). If it was me, i would certainly choose the proven vaccine technology ie INACTIVATED VACCINES.

@Kraboo Exactly. That was what i was trying to say. Not to mention the safety profile is proven compared to other newer unproven vaccine technologies.

Indonesia to Begin Vaccine Programme in November 2020

Indonesia will use vaccines from three companies, namely Cansino, G42/SINOPHARM, and Sinovac.

https://indonesiaexpat.biz/news/indonesia-to-begin-vaccine-programme-in-november-2020/

Sinopharm will make 15 million doses of its dual-dose vaccine this year, and five million doses will begin to arrive in Indonesia by next month.

Sinopharm is aiming to make 50 million more doses for Indonesia next year.

https://www.aa.com.tr/en/asia-pacific/indonesian-team-in-china-to-check-covid-19-vaccines/2008887

The not so hidden additional COSTS of transporting Pfizer and Moderna vaccines which require storage at subzero temperatures to be safe and effective.

"Both Pfizer and Moderna are developing mRNA vaccines, with data signalling that they will need to be transported and stored at ultracold temperatures of minus 70 and minus 24 degrees respectively to ensure their chemical structures remain stable.

If the vaccines become too warm for too long at any point along the “cold chain” – the journey from the point of manufacturing to injection – they may be rendered ineffective.

“I can't emphasise enough the complexity of maintaining an absolute temperature from the depo to the distribution centre to the airplane to the delivery truck to the surgery and the refrigerator in the doctors,” said Nick Jackson, head of programmes and innovative technologies at the Coalition for Epidemic Preparedness Innovations (Cepi).

“It’s incredibly difficult even on a good day with vaccines that are refrigerated. But the challenges are made harder as you begin to lower the temperature requirements,” he added.

Coordinating the supply chain to ensure that these vaccines not only remain cold, but arrive within a time window to use them, is a daunting, COSTLY task – especially when so many vaccines will need to be distributed at once."


https://www.telegraph.co.uk/global-health/science-and-disease/boost-oxford-covid-vaccine-emerges-rivals-must-deep-frozen/

One of the most advanced US coronavirus vaccines, created by Pfizer in partnership with BioNTech, has to be stored at -70° Celsius (-94° Fahrenheit), or around 30°C colder than the North Pole in winter. It’s far from certain that the vaccine will be approved for widespread distribution. But if it is, very few freezers go that cold.

The transport COSTS would be extremely HIGH

https://qz.com/1904638/covid-19-vaccine-states-are-hunting-for-medical-deep-freezers/

This clearly shows the advantage of inactivated vaccines (Sinopharm Covid Vaccine is inactivated vaccine) from the point of view of storage conditions as it only requires a normal refrigerator to store (storage temperature is 2-8C) and is therefore accessible to MANY more people all over the world compared to Moderna and Pfizer Vaccines.


"Among the several COVID-19 vaccines now under development worldwide, only three have advanced to Phase III trials. Of those, candidates from Moderna/NIH and Pfizer/BioNTech must be kept at a near constant deep freeze because they are made with genetic materials that are damaged at warmer temperatures.

Many pharmacies are unlikely have the equipment to store large quantities of vaccines at ultra-cold settings. In August, CDC disease expert Kathleen Dooling warned the White House coronavirus task force that strict temperature requirements "will make it very difficult for community clinics and local pharmacies to store and administer" vaccines. She added that vaccines would have to be dispensed "at centralized sites with adequate equipment and high throughput." Other issues include having sufficient cold-resistant vaccines for a frozen vaccine and equipping transportation and storage facilities with the technology to accommodate super-cold vaccines. A recent study by DHL and McKinsey estimates that vaccines requiring cold storage would be accessible to ONLY about 2.5 billion people in 25 countries."

https://www.pharmacist.com/article/how-ship-vaccine-80-degrees-c-and-other-obstacles-covid-fight

China might be weeks away from a COVID-19 vaccine

Despite President Trump’s insistence that the U.S. is only “weeks away from a vaccine” for COVID-19, top health officials have said the country is “extremely unlikely” to approve a vaccine in October or November. Pfizer has said that in the best-case scenario, it could have final clinical trial data by the end of October, which could lead to official approval a minimum of several weeks later.

In contrast, China is likely closer to approving a vaccine, and Beijing may actually be only weeks away from approving a final candidate and moving forward with a formal, public rollout.

https://www.google.com/amp/s/supchina.com/2020/10/02/china-might-be-weeks-away-from-a-covid-19-vaccine/amp/

Committed to delivering long-term shareholder value, Kuah said: “With the commencement of our new high-tech bamboo processing plant in the fourth quarter of 2020, our financial performance in the coming year will be significantly enhanced by the contributions from the production and sale of our in-house bamboo products.

“Looking ahead, we are confident that demand for bamboo will see exponential growth driven by its increasing use as a sustainable material for construction and rising consumer awareness on the benefits of bamboo.

https://www.thestar.com.my/news/nation/2020/09/10/bamboo-venture-in-china

Global Bamboos Markets Report 2020: Market was Valued at USD 72,102.4 Million in 2019 and is Expected to Reach Over USD 98,757.9 Million by 2026

The global bamboos market was valued at USD 72,102.4 Million in 2019 and is expected to reach over USD 98,757.9 Million by 2026, growing at a CAGR of around 5.5% during the forecast period from 2020 to 2026.

https://www.globenewswire.com/news-release/2020/09/25/2099245/0/en/Global-Bamboos-Markets-Report-2020-Market-was-Valued-at-USD-72-102-4-Million-in-2019-and-is-Expected-to-Reach-Over-USD-98-757-9-Million-by-2026.html

3.7 Future prospects of the Group

In accordance with its strategy to continuously grow its existing business, the Group
had relocated the main bamboo processing and manufacturing plant out of Ganzhou,
and entered into a public private partnership arrangement on a 70:30 basis with the
local authority of Jingzhou, China to develop a new high-tech bamboo processing plant
and research and development center. The aforesaid plant is currently under testing
phase and is expected to commence commercial operations in NOVEMBER 2020, and is
surrounded by an estimated 18,200 metric tonnes of ready-to-harvest raw bamboo,
which will be used for the manufacturing of bamboo products, processing of bamboo
related foodstuff and bamboo eco-tourism in the near future.

In addition, the Group has put in place a research and development team to develop
new range of eco-friendly products to ensure the Group is able to continue catering to
the demands of customers and remain competitive in the industry. The Group being
the sole exclusive distributor in the China for "Classen", a brand of a high-end wood
flooring products originated from Germany, and will continue to focus its efforts to
promote and sell Classen's products. The proceeds raised from the Proposed Private
Placement will ensure that the Group has sufficient working capital for its existing
business to weather any potential headwinds in the short to medium term.

Further, in view of the positive outlook of the HEALTHCARE INDSUTRY as set out in Section
3.6 of this announcement, the management is of the view that now is a timely
opportunity for the Group to venture into a new business, which has growing demand
and may yield favorable and sustainable earnings to the Group over the medium to
long term.

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=107904&name=EA_GA_ATTACHMENTS

China has made it clear that it is willing to make efforts within its capacity in vaccine development, and give priority to the needs of developing countries including the Association of Southeast Asian Nations (ASEAN) countries, Chinese State Councilor and Foreign Minister Wang Yi said Friday.

China will earnestly fulfill its commitment to make vaccines a global public product once they are successfully developed and put into use, and will contribute to the ACCESSIBILITY AND AFFORDABILITY of the VACCINES in DEVELOPING COUNTRIES, said Wang.

https://webcache.googleusercontent.com/search?q=cache:IFrppnN9uXYJ:https://www.thestar.com.my/news/world/2020/10/17/china-willing-to-help-more-countries-access-to-covid-19-vaccine-fm+&cd=2&hl=en&ct=clnk&gl=my

China has made it clear that it is willing to make efforts within its capacity in vaccine development, and give priority to the needs of developing countries including the Association of Southeast Asian Nations (ASEAN) countries, Chinese State Councilor and Foreign Minister Wang Yi said Friday.

Wang made the remarks in an exclusive interview with Xinhua after he held talks last week with Luhut Binsar Pandjaitan, Indonesian president's special envoy, and Philippine Foreign Secretary Teodoro Locsin in southwest China's Yunnan Province, and wrapped up Friday his Southeast Asia tour, which has taken him to Cambodia, Malaysia, Laos, Thailand and Singapore.

China is ready to help more countries get access to and be able to afford the vaccines
http://www.xinhuanet.com/english/2020-10/17/c_139445918.htm

Dow advances, S&P ekes out gain as vaccine timeline comes into focus

https://economictimes.indiatimes.com/markets/stocks/news/dow-jones-climbs-on-vaccine-hopes-upbeat-retail-sales-data/articleshow/78704270.cms

On separate topic regarding Bamboos :

Bamboos Market Size Worth a whopping $98.3 Billion By 2025 | CAGR: 5.0%

Research, Inc. The market is projected to register swift growth on account of the growing infrastructural development and use of sustainable resources in the manufacture of furniture and industrial products across the globe.

Bamboo and rattan can be cultivated easily without a need for chemical pesticides and fertilizers. They grow rapidly and do not require replanting. Further, processing of bamboo and rattan for the manufacture of processed products such as flooring, pulp & paper, and furniture has a relatively low environmental impact. Furthermore, bamboo and rattan offer a renewable and low-carbon alternative over plastics and hardwood. Thus, the growing environmental awareness concerning carbon emission is expected to boost the demand for bamboos products over the forecast period.

https://www.grandviewresearch.com/press-release/global-bamboos-market

Sinopharm Inactivated Vaccine has the advantage in terms of storage condition (typical 2-8 degrees Celsius) and distribution to developing countries. Tell me which developing country, especially the rural areas have the facilities to store Moderna and Pfizer Vaccines at subzero temperatures?? It is obviously meant for rich developed countries with an abundance of such facilities and not developing and poor countries.

"Traditional vaccines (This refers to vaccines such as inactivated vaccines) are usually stored between 35 degrees Fahrenheit and 46 degrees Fahrenheit (2-8 degrees Celsius), but some of the leading COVID-19 vaccines need to be stored at much colder temperatures. Moderna’s vaccine requires a storage temperature of minus 4 degrees Fahrenheit (- 20 degrees Celsius !), whereas Pfizer’s vaccine candidate requires a storage temperature of minus 94 degrees Fahrenheit (-70 degrees Celsius!!). These are not easy temperatures to maintain accurately."

https://theconversation.com/keeping-coronavirus-vaccines-at-subzero-temperatures-during-distribution-will-be-hard-but-likely-key-to-ending-pandemic-146071#:~:text=Most%20vaccines%20need%20to%20be,stored%20at%20much%20colder%20temperatures.

"Moderna and Pfizer’s COVID-19 vaccine candidates require ultra-low temperatures, raising questions about storage, distribution"

https://www.marketwatch.com/story/moderna-and-pfizers-covid-19-vaccine-candidates-require-ultra-low-temperatures-raising-questions-about-storage-distribution-2020-08-27

Sinopharm Covid Vaccine is INACTIVATED vaccine

"From adenoviruses to RNA: the pros and cons of different COVID vaccine technologies

3. INACTIVATED
Inactivated vaccines are a tried and trusted method of vaccination. It’s the technology used in the vaccine against poliovirus and in some types of flu vaccines. Inactivated vaccines contain viruses treated with heat, chemicals, or radiation so they cannot replicate, but can still trigger an immune response.

A known technology, generally considered SAFE

Can be used in people with weakened immune systems."

https://theconversation.com/from-adenoviruses-to-rna-the-pros-and-cons-of-different-covid-vaccine-technologies-145454

Think about it, would you rather subject yourself to unproven vaccine approaches/ platforms or traditional vaccine approaches/platforms (such as inactivated vaccine technology. One good example would be inactived flu vaccine) which is well established and have widespread and long history of safe and effective used globally. Why do you think recently Astrazeneca and Johnson and Johnson vaccines (based on Adenovirus vector vaccine platform) reported side effects with their vaccines?

"Most of the frontrunners in the COVID-19 vaccine race are using relatively unproven approaches to immunization. BioNTech, in partnership with Pfizer, and Moderna are advancing mRNA vaccines, a type of prophylactic that has never been approved. AstraZeneca, CanSino and Johnson & Johnson are taking a viral vector approach that is barely more established than mRNA"

Safety is an area Sinopharm thinks it might have an edge. With 15% of subjects experiencing adverse reactions, the authors argue the Sinopharm prospect has “a relatively better safety profile compared with vaccines using other platforms.”

https://www.fiercebiotech.com/biotech/sinopharm-shares-phase-2-data-inactivated-covid-19-vaccine

According to a recent report by SinoLink Securities, developing inactivated vaccines usually takes more time compared with newer technologies of nucleic acid and recombinant vaccines because the traditional method has strict R&D conditions including high biosafety standards.

But once successfully synthesized, inactivated vaccines can be massively produced while it is often difficult to produce vaccines using new technologies on a large scale due to a lack of production capacity, the report said.

http://global.chinadaily.com.cn/a/202004/30/WS5eaa3afea310a8b241152e89_2.html

Can anyone explain why the price keep dropping? Is it safe to enter at this price? Afraid it drops some more.

Nobody is asking you both to be here

This forum will be better off without you both kekeke

@rezzare @reezdragon85 I am not sharing for well informed people like you but for those who are not up to date on the news. So if you are not happy with my spamming, then just leave this forum

Malaysia dijangka tandatangani COVAX dua minggu lagi / Malaysia is expected to sign COVAX in two weeks time

https://www.bharian.com.my/berita/nasional/2020/10/742464/malaysia-dij...

“I am quite pleased with this guarantee and I have asked that this cooperation be inked in the form of an MoU to be made with CHINA,” he told a press conference at his residence in Putrajaya today.

Muhyiddin said the government had also agreed to join the COVID-19 Vaccine Global Access (COVAX) Facility, a global partnership that can help developing nations obtain vaccines for COVID-19 and other diseases.

Muhyiddin said although this would involve a huge amount of money, it would not stop the government from obtaining the supply from vaccine suppliers from other sources.

https://www.pmo.gov.my/2020/10/covid-19-vaccine-malaysia-to-ink-mou-with-china-pm/

Earlier, Coordinating Minister for Maritime Affairs and Investment Luhut Binsar Pandjaitan met with the leaders of Chinese vaccine manufacturers, including Cansino, SINOPHARM and Sinovac in the southwestern Chinese province of Yunnan over the weekend.

His ministry said in a press release that the three companies have agreed to supply vaccines that have entered the third phase of clinical trials.

https://www.aa.com.tr/en/latest-on-coronavirus-outbreak/indonesia-steps-up-efforts-to-secure-covid-19-vaccine/2003680

Malaysia Joins COVAX Vaccine Plan, Also In Deals With China, Pharma Companies

https://codeblue.galencentre.org/2020/09/19/malaysia-joins-covax-vaccine-plan-also-in-deals-with-china-pharma-companies/

CNBG, a biotech entity of the state-owned China National Pharmaceutical Group Sinopharm (Sinopharm), has conducted clinical research in several countries including the United Arab Emirates, Bahrain, Argentina, Peru, and Morocco, according to its vice president and chief scientist Zhang Yuntao.
According to media reports, the company’s international clinical trial plan has involved more than 50,000 volunteers from 115 countries.

https://www.enterprisetv.com.my/chinas-covid-19-vaccines-expected-to-be-publicly-available-by-year-end/

China has signed up to a deal to ensure future Covid-19 vaccines are distributed to developing countries, the biggest economy yet to join the World Health Organisation-led bid to control the pandemic.

The COVAX pledge to get vaccines to poorer nations as soon as they are developed aims to head off fears rich countries will limit distribution of game-changing medicines made by their pharmaceutical companies.

The deal gives China, the country where the virus first emerged, a prominent role in the global effort to share vaccines with less-developed countries.

China joined COVAX to "honour its commitment to turn Covid-19 vaccines into a global public good," foreign ministry spokeswoman Hua Chunying said Friday of the Oct 8 agreement.

https://www.thestar.com.my/aseanplus/aseanplus-news/2020/10/09/china-joins-deal-to-get-covid-19-vaccine-to-poorer-nations